Phathom Pharmaceuticals' (PHAT) shares were down 3.3% in recent Thursday trading after the company reported a Q3 net loss of $1.05 per diluted share, wider than a loss of $0.54 a year earlier.
Two analysts polled by Capital IQ projected a loss of $1.47 per share.
Net revenue for the quarter ended Sept. 30 was $16.4 million, with no year-ago revenue reported.
Analysts surveyed by Capital IQ expect $12.4 million.
"There were no revenues for the third quarter 2023 due to the launch of Voquezna taking place in the fourth quarter 2023," according to the company.
Phathom received approval from the US Food and Drug Administration in July for Voquezna tablets for the relief of heartburn related to non-erosive gastroesophageal reflux disease in adults.
Price: 17.41, Change: -0.59, Percent Change: -3.31
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。